News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched
Subscribe To Our Newsletter & Stay Updated
